Table 1.
Classes of drugs | Mechanism of action | Therapeutic issues |
---|---|---|
Antidepressants (SSRIs, TCADs, SNRIs) | Neurotransmitters reuptake inhibitors | Reduction of abdominal pain; limited data about safety and tolerability |
Benzodiazepines | Enhancement of GABA inhibitory effect | Limited use; risk of tolerance and rebound withdrawal; lack of reliable antidepressant efficacy |
Atypical Antipsychotics (Quetiapine) | Receptorial antagonism with dopaminergic (D2) and serotoninergic (5-HT2) receptors | Possible use only in patients with severe psychiatric comorbidities; lacking data and evidence about efficacy and safety in irritable bowel syndrome |
SSRIs: selective serotonin reuptake inhibitors. TCADs: trycyclic antidepresants. SNRIs: serotonin norepinephrine reuptake inhibitors. 5-HT: 5-hydroxytriptamine.